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dBACKGROUND & AIMS: Some patients with irritable
bowel syndrome (IBS)-like symptoms suffer from food hyper-
sensitivity (FH); their symptoms improve when they are placed
on elimination diets. No assays identify patients with FH with
satisfactory levels of sensitivity. We determined the frequency of
FH among patients with symptoms of IBS and the ability of
fecal assays for tryptase, eosinophil cationic protein (ECP), or
calprotectin to diagnose FH.METHODS: The study included
160 patients with IBS, 40 patients with other gastrointestinal
diseases, and 50 healthy individuals (controls). At the start of
the study, patients completed a symptom severity question-
naire, fecal samples were assayed, and levels of specific immu-
noglobulin E were measured. Patients were observed for 4
weeks, placed on an elimination diet (without cow’s milk and
derivatives, wheat, egg, tomato, and chocolate) for 4 weeks, and
kept a diet diary. Those who reported improvements after the
elimination diet period were then diagnosed with FH, based on
the results of a double-blind, placebo-controlled, oral food
challenge (with cow’s milk proteins and then with wheat pro-
teins). RESULTS: Forty of the patients with IBS (25%) were
ound to have FH. Levels of fecal ECP and tryptase were
ignificantly higher among patients with IBS and FH than
hose without FH. The ECP assay was the most accurate
ssay for diagnosis of FH, showing 65% sensitivity and 91%
pecificity. CONCLUSIONS: Twenty-five percent of pa-
tients with IBS have FH. These patients had increased
levels of fecal ECP and tryptase, indicating that they
might cause inflammation in patients with IBS. Fecal
assays for ECP could be used to identify FH in patients
with IBS.
Keywords: Cow’s Milk Protein Hypersensitivity; Gluten Sensitiv-
ity; Fecal Tryptase; Fecal Eosinophil Cationic Protein; Fecal
Calprotectin.
Watch this article’s video abstract and others at http://
tiny.cc/bz9jv.
Scan the quick response (QR) code to the left with
your mobile device to watch this article’s video ab-
stract and others. Don’t have a QR code reader? Get
one at mobiletag.com/en/download.php.Irritable bowel syndrome (IBS) is a common gastrointestinaldisorder which accounts for about 40% of all gastroenterol-
gy outpatient consultations.1 Although an alteration of the
rain-gut axis is considered to have a fundamental role,2 gut
mucosal inflammation is certainly important in the complex
pathogenesis of IBS.3 In fact, several studies have shown an
ncreased number of immunocytes both in the lamina propria
nd in the epithelium of mucosal biopsy specimens from IBS
atients.4–10 Lamina propria and intraepithelial lympho-
ytes,5,10 mast cells,4,7,9 and macrophages11 are among the im-
munocytes involved in mucosal inflammation in IBS, and a role
for a previous infectious enteritis in determining this inflam-
mation has been established.11,12 However, it is also known that
ietary factors might be important in the pathogenesis of IBS3
and the same inflammatory cells, together with eosinophils, are
the immunologic effectors of food hypersensitivity (FH).13–17
As many symptoms of IBS are common to FH—abdominal
pain and/or discomfort, bloating, alteration of bowel habits—
differential diagnosis between these 2 conditions is difficult.
In this study involving IBS patients, we aimed to: (1) evaluate
the frequency of FH diagnosis; and (2) investigate the diagnos-
tic accuracy of 3 fecal markers—calprotectin, tryptase, and eo-
sinophil cationic protein—in FH diagnosis.
Methods
One hundred sixty patients (127 females, 33 males, age
range 18–60 years, median age 33 years), who had been con-
secutively referred for IBS as outpatients to 2 internal medicine
clinics (University Hospital of Palermo and Ospedali Civili
Riuniti of Sciacca, both in Italy) from February 2007 to June
2009, completed this study.
The inclusion criteria were identical to those recently used18:
(1) age 17 years, (2) no previous referral to our clinics, and (3)
diagnosis of IBS. Patients with a diagnosis of organic gastroin-
testinal disease were excluded.
Abbreviations used in this paper: CV, coefﬁcient of variation; DBPC,
double-blind placebo-controlled oral food challenge; ECP, eosinophil
cationic protein; FH, food hypersensitivity; HLA, human leukocyte an-
tigen; IBS, irritable bowel syndrome; PBS, phosphate-buffered saline;
tTG, tissue transglutaminase.
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966 CARROCCIO ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 9, No. 11IBS diagnosis was based on the Rome II criteria for func-
tional gastrointestinal disorders19 and organic gastrointestinal
disorders were excluded by an accurate work-up (see Supple-
mentary Methods).
After inclusion, the patients underwent a clinical evaluation,
which included a detailed family and personal clinical history
and a physical examination. A predesigned questionnaire, re-
garding the type and severity of the symptoms, was adminis-
tered to all patients.
None of the enrolled patients were taking any medication at
the time of the study.
The Ethics Committee of the University Hospital of Palermo
approved the study and all patients gave their informed consent
to participate.
Healthy and Disease Control Groups
Two control groups were selected to compare fecal
assay values. One was composed of 40 patients with various
gastrointestinal diseases (30 females, 10 males, age range 18–59
years, median 31 years): celiac disease (n  16), active ileoco-
lonic Crohn’s disease (n 18), and intestinal giardiasis (n 6),
diagnosed according to standard serologic, endoscopy, and his-
tology criteria. The other group was composed of 50 healthy
volunteers (38 females, 12 male, age range 18–60 years, median
30 years).
Study Protocol
After enrollment in the study, the patients completed
the “symptom severity” questionnaire (see Supplementary
Methods) and underwent serum total and food allergen-specific
IgE determination, together with the fecal assays. The diagnos-
tic tests were performed by different operators, unaware of the
clinical history of the patients and the results of the other tests.
The study design was identical to one recently described.18 In
brief, patients were observed for a 4-week run-in period. After
this they underwent a 4-week elimination diet without cow’s
milk and its derivatives, wheat, egg, tomato, and chocolate.
Patients self-reporting FH were also asked to avoid ingestion
and/or contact with the food(s) causing symptoms. The pa-
tients wrote a dietary diary and adherence to the elimination
diet was evaluated by trained dieticians. Patients who referred a
symptom and/or sign improvement after the elimination diet
period underwent a double-blind placebo-controlled oral food
challenge (DBPC), first with cow’s milk proteins and then with
wheat proteins.20
After FH had been excluded or confirmed, all IBS patients
were invited to continue the follow-up with regular visits every
6 months for 2 years. Particular attention was paid when ex-
cluding celiac disease diagnosis in FH patients (see Supplemen-
tary Methods).
Double-Blind Placebo-Controlled Challenges
DBPC for cow’s milk and wheat were performed as
previously described18,20 (see Supplementary Methods).
Serum Total IgE and Food Allergen-Specific
IgE Antibodies
Serum samples from all patients were collected and
analyzed for serum total IgE and food allergen-specific IgE
antibodies by using the Phadia CAP-system (Phadia, Uppsala,
Sweden). The following common food allergens were tested:egg, cow’s milk, soy, peanut, wheat, tomato, and fish. Levels
greater than or equal to 0.35 kU/L (level 1 on the specific IgE
scale) were considered positive. Total IgE was also determined
by the same method with a detection limit of 2 kU/L and an
upper limit of 5000 kU/L. The normal limit for total IgE was
100 kU/L.
Preparation of Stool Samples
Patients were instructed to defecate directly into a poly-
styrene container (diameter 15 cm, depth 12 cm). Stool samples
obviously contaminated with urine were excluded from analy-
sis. For details and methods of tryptase, eosinophil cationic
protein (ECP) and calprotectin assays, see Supplementary Meth-
ods.
Statistical Analysis
The 2 test was used for frequency comparison. Range
nd median values were calculated for each stool assay. Value
omparison of the fecal assays was performed using the Mann–
hitney test. The Wilcoxon rank-sum test was used to compare
he symptoms score before and after the diet treatment. Tables
ere constructed for frequency and percentage. The sensitivity,
pecificity, and diagnostic accuracy of food-specific IgE and
ecal assays, along with their 95% confidence intervals, were
alculated by standard statistical methods.21
To minimize type I errors, P  .05 was considered statis-
tically significant. All statistical analyses were performed
using the SPSS 11.0 statistical package (Systat Software, Inc,
Chicago, IL).
Results
During the study period, a total of 198 patients fulfilled
the Rome II criteria for IBS diagnosis, but the clinical work-up
demonstrated that 38 of them suffered from organic diseases
(15 with celiac disease, 10 lactose intolerance, 5 small bowel
bacterial overgrowth, 3 large colon adenoma 3 cm and high
degree dysplasia, 3 colon cancer, and 2 intestinal giardiasis).
After the 4 weeks of run-in observation period, the remain-
ing 160 patients underwent elimination diet. Table 1 summa-
rizes the number of patients with an improved (score reduction
50), unchanged or worsened (score increase 50) symptom
score on elimination diet. In the 90 patients with unchanged or
Table 1. Number and Percentage of IBS Patients With
Scores Improved, Unchanged, or Worsened During
a 4-Week Period of Elimination Diet
Patients
improved
Patients
unchanged
Patients
worsened
umber and
percentage
70 (44%) 61 (38%) 29 (18%)
core at baseline 330  80a 325  75 315  75
Score during the diet 150  65a 305  85 390  90
NOTE. Symptom severity scores before and after elimination diet are
also shown (mean  SD). Cow’s milk and its derivatives, wheat, egg,
tomato, and chocolate, were excluded in all subjects. The patients
with self-reported food hypersensitivity also avoided food-causing
symptoms.
aP  .0001 Wilcoxon rank-sum test.
ccord
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unrelated to FH was made.
The other 70 patients showing a significant reduction in
symptom score on elimination diet underwent DBPC chal-
lenges. Thirty patients were positive for both cow’s milk and
wheat protein challenges, 6 were positive exclusively for cow’s
milk challenge, and 4 were positive exclusively for wheat chal-
lenge. In total, 40 patients were positive for DBPC food chal-
lenges. In all DBPC-positive patients, symptoms (abdominal
pain, bloating, diarrhea, constipation, etc) reappeared after a
median period of 2.5 days (range 1–8 days) after commencing
the challenge with cow’s milk or wheat proteins. Twenty-four of
these 40 patients did not complete the challenge period with
the “active food” due to the severity of symptoms. None of these
patients reacted on placebo administration.
The 40 patients with positive DBPC challenges to cow’s milk
and/or wheat proteins fulfilled the Rome II criteria for IBS
diagnosis and were diagnosed with FH.
The other 30 patients, who improved on elimination diet,
did not react to the DBPC challenges; these subjects also un-
derwent open challenges with other foods and did not react.
Consequently, they were diagnosed with IBS not related to FH.
Of the whole group composed of 160 IBS patients, 40 sub-
jects (25%) had a final diagnosis of FH and significantly im-
Figure 1. Main results aproved or were cured on the elimination diet.Figure 1 summarizes the results, according to the study
design.
According to the results of the elimination diet and the
subsequent DBPC challenges, the patients were then divided
into 2 subgroups: group A (FH), including the subjects with
scores improved on elimination diet and positive to DBPC
challenge with cow’s milk and/or wheat proteins (n  40) and
group B (IBS not related to FH), including the subjects with
scores unchanged or worsened on elimination diet and the
patients with negative DBPC challenge for cow’s milk and
wheat proteins (n  120).
Patients of group A and group B did not differ for sex, age,
symptom severity score at entry to the study, clinical character-
istics (frequency of predominant diarrhea or constipation or
alternating bowel habits), or frequency of associated atopy.
However, the duration of IBS symptoms was significantly
higher in patients with FH (mean SD: 11.4 4.2 vs 6.4 5.2
years; P  .001). Furthermore, the FH patients showed a higher
frequency of self-perceived food intolerance (32 of 40 vs 24 of
120; P  .01) and of history of food hypersensitivity during
infancy (10 of 40 vs 9 of 120; P  .02). Twenty-two of forty
(55%) FH patients showed the DQ2 or DQ8 haplotypes.
Figure 2 shows median and first and third quartile values of
fecal tryptase in the patients of group A and group B, as well as
ing to the study design.in the 2 control groups (“healthy” and “disease” controls).
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968 CARROCCIO ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 9, No. 11Tryptase values were significantly higher in FH patients than in
patients with IBS not related to FH (P  .001) and healthy
controls (P  .001); whereas there was no difference between
FH patients and “disease” controls. Patients with IBS not re-
lated to FH had tryptase values significantly higher than
healthy controls (P  .02) and significantly lower than “disease
controls” (P  .002).
A similar pattern was seen for ECP (Figure 3). Values were
significantly higher in FH patients than in IBS patients not
related to FH (P  .0001) and healthy controls (P  .0001);
disease controls” showed values significantly higher than FH
atients. Patients with IBS not related to FH had ECP values
imilar to healthy controls and significantly lower than “disease
ontrols” (P  .0001).
As regards calprotectin values, there was no difference be-
ween IBS patients with FH and those with IBS unrelated to
Figure 2. Fecal tryptase values in 40 patients suffering from FH, in 120
subjects suffering from different gastrointestinal diseases (disease cont
Figure 3. Fecal ECP values in 40 patients suffering from FH, in 120 p
suffering from different gastrointestinal diseases (disease controls).H, nor between these 2 groups and “healthy” controls. How-
ver, “disease controls” showed values significantly higher than
he other groups.
No differences in the values of the 3 fecal markers were
ound between patients with predominant constipation and
atients with predominant diarrhea within group A and group
(see Supplementary Table 1).
Table 2 shows the number of positive and negative results of
he immunologic assays in the IBS patients and in the healthy
nd “disease” controls. According to these results, Table 3
hows the sensitivity, specificity, and diagnostic accuracy of the
mmunologic assays in the diagnosis of FH in patients with a
linical presentation of IBS. Fecal ECP assay showed the highest
ensitivity, specificity, and diagnostic accuracy among the as-
ays performed. ECP sensitivity was higher than those of tryp-
ase (2 7.2; P  .01) and calprotectin (2 6; P  .02). ECP
nts with IBS not related to FH, in 50 healthy controls, and in 40 control
s with IBS not related to FH, in 50 healthy controls, and in 40 controlspatieatient
n
r
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results among healthy subjects; it was significantly higher than
those of tryptase (2 4; P  .05), calprotectin (2 3.9; P  .05),
and food-specific IgE (2 3.9; P  .05). However, high values of
ECP were also found in the “disease” controls, mainly in pa-
tients with chronic inflammatory bowel disease and intestinal
parasitosis.
It was noteworthy that 8 of the 16 FH patients negative for
serum specific IgE showed elevated fecal ECP values.
All patients included in the study were followed up for a
2-year period, during which they were reassessed at intervals of
6 months. FH patients continued to follow an elimination diet
with the exclusion of the foods causing the IBS symptoms and
all referred the persistent disappearance of symptoms or a
consistent improvement. Symptom score at entry to the study
was 365  75, at 6 months 170 55, at 12 months 160 45,
at 18 months 140  60, at 24 months 145  45. Occasional
ingestion of the eliminated foods always caused the recurrence
of the IBS symptoms. Furthermore, all patients referred multi-
ple hypersensitivity to other foods, which we evaluated with
elimination diets and open challenges. Apart from cow’s milk
and wheat, the following foods caused IBS-like symptoms: egg
able 2. Results of the Fecal Assays and of Serum Specific
IgE in the Patients With IBS Unrelated to FH (n 
120), in Those With FH (n  40), in the Healthy
Controls (n  50), and in the “Disease” Controls
(n  40)
Tryptase ECP Calprotectin
Serum-specific
IgE
IBS unrelated to FH
Positive 23 11 22 24
Negative 97 109 98 96
IBS related to FH
Positive 13 26 14 24
Negative 27 14 26 16
Healthy control
group
Positive 2 0 1 0
Negative 48 50 49 40
Disease control
group
Positive 14 29 31 8
Negative 26 11 9 32
OTE. Reference values were: tryptase  2.4 g/L; ECP  1 g/g;
calprotectin  50 g/kg food allergen-specific IgE antibodies  0.35
kU/L. The following antigens were used in the serum specific IgE
assay: alpha-lactalbumin, beta-lactoglobulin, casein, wheat proteins.
Positivity for 1 of them was considered as “positive assay,” negativity
for all was considered as “negative assay.”
Table 3. Sensitivity, Specificity, and Diagnostic Accuracy (95
Specific IgE in the Diagnosis of FH in Patients With
Fecal tryptase Fec
Sensitivity 33 (24–53) 65
Specificity 81 (71–89) 91
Diagnostic accuracy 69 (59–77) 84
NOTE. Data are shown as %. Statistics: sensitivity of fecal ECP vs t
specificity of fecal ECP vs tryptase P  .05, vs calprotectin P  .05, vs s(18 cases), tomato (14 cases), soy (5 cases), yeast (6 cases), pork
(3 cases), prawn (4 cases), fish (5 cases), celery (3 cases), olive (2
cases), nuts (3 cases), carrot (2 cases), and meat (3 cases).
During the follow-up, some patients underwent further exam-
inations: colonoscopy (5 cases), esopho-gastroscopy and duodenal
biopsies (8 cases)— which were all negative. Serum assays for celiac
disease (anti-tissue transglutaminase [tTG] and anti-endomisyum
antibodies) were regularly repeated every 6 months in all FH
patients and were always negative.
Ninety-nine of the IBS patients unrelated to FH completed
the 2-year follow-up and 21 were lost. In most of these subjects
IBS symptoms persisted periodically, despite several treatments.
None of them were found to be suffering from an “organic”
cause of symptoms.
Discussion
IBS is a complex disease and genetic, neurobiological,
and psychosocial factors are involved in its pathogenesis. Re-
cently, the role of microscopic inflammation and immune ac-
tivation in the intestinal mucosa has been elucidated.3,5,22 Gas-
trointestinal infections are more likely to initiate IBS-like
symptoms23 inducing mucosal inflammation. Impaired intesti-
al permeability24 and a role for mucosal inflammation in
egulating the gut-brain axis25 have also been reported.
However, it is well known that both mucosal inflammation
and impaired intestinal permeability can be due to food hyper-
sensitivity;26 furthermore, many patients suffering from IBS
report an association of symptoms with specific food ingestion.
Numerous recent reports18,27,28 have demonstrated that a sub-
group of IBS patients suffers from FH and these subjects
improve on elimination diet. However, the relationship between
FH and IBS is still considered controversial and it is difficult to
distinguish between these conditions because both IBS and FH
with gastrointestinal symptoms often have the same clinical
presentation. Furthermore, none of the available in vivo and in
vitro allergy tests (ie, skin prick test and serum total IgE and
specific IgE assays) have a good diagnostic reliability.29
In this study we evaluated a large group of IBS patients and,
using a rigorous diagnostic approach—based on elimination
diet and DBPC challenge—identified those suffering from FH.
Forty IBS patients were positive on DBPC challenge with cow’s
milk and/or wheat proteins and consequently a high percentage
(40/160, 25%) of cases were diagnosed as FH. In these patients,
symptom severity significantly regressed on elimination diet,
while numerous previous treatments had not been effective. As
34 out of 160 patients (22%) showed gluten hypersensitivity, it
would be interesting to place these subjects in the complex
category of gluten sensitivity.30 Previous works have demon-
trated that gliadin can induce an increased intestinal permea-
ility and innate immune cell activation. However, these studies
nfidence Interval) of the Fecal Assays and Serum Food-
cal Presentation of IBS (n  160)
P Fecal calprotectin Food-specific IgE
8) 35 (22–50) 60 (45–73)
5) 82 (72–88) 80 (76–90)
0) 70 (58–75) 75 (66–83)
se P  .02, vs calprotectin P  .01, vs specific IgE not significant;% Co
Clini
al EC
(50–7
(82–9
(75–9
rypta
pecific IgE P  .05.
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970 CARROCCIO ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 9, No. 11on animal models observed these effects only in genetically
susceptible subjects.31,32 In our study, the DQ2 or DQ8 human
eukocyte antigen (HLA) haplotypes was present only in 22/
0 (55%) of FH subjects, and it is noteworthy that most patients
ere suffering from both wheat- and cow’s milk-protein hyper-
ensitivity. Consequently, other non-DQ2/DQ8 related mecha-
isms should be investigated.
As regards the fecal assays, the distribution of tryptase and
CP values was very interesting, whereas fecal calprotectin did
ot seem to be useful in distinguishing between FH and IBS.
The highest tryptase values were seen in FH subjects with
rogressively decreasing—and significantly different—levels in
BS and healthy control subjects. It is known that stimulation
f mast cells with IgE-dependent or non–IgE-dependent ago-
ists leads to the release of preformed and newly-synthesized
nflammatory mediators. Therefore, tryptase, a serine protei-
ase, released almost exclusively by mast cells, may be suitable
s a marker of mast-cell activation in patients with FH. More-
ver, we showed that a high concentration of mast cell-derived
roteins in the stools is characteristic of IBS, independently of
oexistent FH3,4,7–9 and, in fact, these patients showed signifi-
antly higher tryptase values than healthy controls. However,
ur data indicate the first evidence that fecal tryptase levels (and
he underlining mast cell infiltration) is more intensive in FH
han in IBS not related to FH. Further studies should clarify
hether the elimination diet can improve the previously dem-
nstrated mast cell mucosal inflammation and the neural dam-
ge which has been reported in IBS.3,4,7–9 In fact, the relation-
hip between FH and dismotility in pediatric patients has been
learly demonstrated.20,33–35
ECP might be as useful in FH patients as it is in patients
with respiratory allergic diseases.36 In our study, fecal ECP
values were 2-fold higher in FH than in IBS patients or in
healthy control subjects. Furthermore, IBS patients had ECP
values virtually identical to healthy control subjects. Conse-
quently, fecal ECP seems to be a specific marker of intestinal
inflammation due to FH. Previous studies on ECP in adults
with FH have included very few patients, prediagnosed as suf-
fering from FH. Magnusson et al. showed an increase in fecal
ECP in 13 FH patients after food challenge37 and 8 of these
atients fulfilled the Rome II criteria of IBS. However, in our
tudy, ECP assay showed an overall sensitivity of 65% and we
ound elevated values in the “disease” control group, so in a
linical setting it may not distinguish between other organic
isease and food hypersensitivity.
In conclusion, our study demonstrated that a relatively high
ercentage of IBS patients are actually suffering from FH and
onfirmed that this diagnosis is difficult as FH symptoms are
ery often very delayed.38 In these patients tryptase and ECP are
mong the pivotal mediators of inflammation; consequently,
ryptase and mast cells can be markers of FH rather than of
rior gastroenteritis. Fecal assays of ECP may be useful in
dentifying FH patients among IBS-presenting subjects.
Supplementary Material
Note: To access the supplementary material accompa-
nying this article, visit the online version of Clinical Gastroenter-
ology and Hepatology at www.cghjournal.org, and at doi:10.1016/
j.cgh.2011.07.030. 2References
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Rome II Criteria for IBS Diagnosis
The included patients had suffered from recurrent ab-
dominal discomfort or pain at least 3 days per month in the
previous 3 months, associated with 2 or more of the following:
(1) improvement with defecation; (2) onset associated with a
change in stool frequency; or (3) onset associated with a change
in stool appearance.
Work-up for IBS Diagnosis
All patients underwent first-step hematology and chem-
istry tests (including erythrocyte sedimentation rate, serum
C-reactive protein, blood cell counts, electrolytes, and thyroid,
liver, and renal function), serologic assays for celiac disease
(anti-transglutaminase IgA and IgG), stool examination for
occult blood, ova and parasites, and a lactose-H2 breath test.
Patients also underwent sigmoidoscopy with biopsy if under 40
or colonoscopy with biopsy if over 40 years of age. Patients with
negative results for all of the examinations described above and
with a clinical history indicating IBS, according to the Rome II
criteria, were considered to be suffering from IBS and were
enrolled in the study.
Clinical Follow-up and Methods to Exclude a
Diagnosis of Celiac Disease
Clinical follow-up was performed with regular visits
every 6 months for 2 years. During the follow-up visits the
patients again underwent physical examination, clinical history,
and routine hemato-chemical assays and when considered op-
portune some instrumental examinations were repeated. Partic-
ular attention was paid in excluding celiac disease diagnosis in
FH patients.
At the entry in the work-up evaluation, the patients who had
regularly eaten wheat underwent serologic assays for celiac
disease (anti-transglutaminase IgA and IgG—anti-tTG IgA and
IgG) and if the results were negative they were included. Pa-
tients with a recent history of reduced wheat consumption were
instead asked to reintroduce wheat into the diet and anti-tTG
IgA and IgG assays were repeatedly performed. Furthermore,
these subjects underwent HLA determination to search for DQ2
or DQ8 or the single DQB102 allele. Patients with negative
serum anti-tTGs not carrying the alleles for DQ2 or DQ8 or
the DQB102 allele were considered not to be suffering from
celiac disease. Patients carrying the alleles for DQ2 or DQ8
or the DQB102 allele, although negative for serum anti-
tTGs, underwent duodenal biopsy after regular wheat con-
sumption and symptoms reappearance. A normal villi aspect
(villi:crypts ratio 3) and a normal intraepithelial lympho-
cytes count (25 intraepithelial lymphocytes and/or 100
enterocytes) were considered to exclude a celiac disease di-
agnosis. Patients with doubtful histology were excluded and
re-evaluated during the follow-up.
HLA was also determined in all patients with a definitive
diagnosis of gluten sensitivity who had not undergone this
assay at the entry in the study.
Symptoms Questionnaire
Symptoms were assessed using a questionnaire scoring
system validated for use in IBS, including an IBS symptom
severity score (range 0–500). This is a system for scoring pain,distension, bowel dysfunction, and general well-being, with
mild, moderate, and severe cases indicated by scores of 75 to
175, 175 to 300, and 300, respectively. A reduction in score of
50 or more was regarded as a clinically significant improvement,
whereas an increase in score of 50 or more was considered as a
clinically significant worsening.21
Double-Blind Placebo-Controlled Challenges
DBPC for cow’s milk was performed by administering
capsules coded as A or B containing milk proteins (daily dose
11 g, equal to the protein content of 300 mL of cow’s milk) or
xylose, respectively. DBPC for wheat proteins was performed
with capsules coded as C or D containing wheat (daily dose
13 g, equal to the protein content of 100 g of bread) or xylose,
respectively. Capsules A or B were given for 2 consecutive weeks,
and then after 1 week of washout the patients received the other
capsules for another 2 weeks. After 1 week of washout, capsules
C or D were given for 2 consecutive weeks, then after another
week of washout, the patients received the other capsules for 2
weeks. The challenges were stopped when a clinical reaction
occurred, ie, the onset of abdominal discomfort or pain, asso-
ciated with a change in stool frequency and/or appearance.
Preparation of Stool Samples (Further
Details)
An aliquot of 1 g was separated and stored at 80°C
ntil analysis. After thawing, overnight in the refrigerator or at
oom temperature using a fan, approximately 100 mg of feces
ere taken and diluted in an extraction buffer (weight:volume
atio 1:50), consisting of phosphate-buffered saline (PBS), sup-
lemented with 12 mmol/L ethylenediamine tetraacetic acid,
.1% N-cetyl-trimethyl ammonium bromide, 20% glycerol,
.005% Tween 20, and 1% bovine serum albumin, and a protease
nhibitor cocktail (Sigma-Aldrich, Saint Louis, Missouri, USA),
ontaining 4 mmol/L 4-(2-aminoethyl)-benzensulfonyl fluo-
ide, 0.26 mmol/L bestatin, 28 mol/L E-28, 2 mol/L leupep-
tin, and 0.6 mol/L aprotinin, pH 7.4. The mixture was then
omogenized using a Polytron mixer (Glen Mills, Inc., Clifton,
ew Jersey) until a homogenous solution was obtained (ap-
roximately 10–90 seconds). The homogenate (1 mL) was cen-
rifuged at 20,000g for 30 minutes and the clear extract super-
atant (0.5 mL) collected and frozen at 20°C for later
measurement.
Fecal Markers Assays
Measurement fecal tryptase. Fecal tryptase concen-
ration was analyzed by immunoassay performed in duplicate
sing the ImmunoCAP system (Pharmacia Diagnostics, Upp-
ala, Sweden) according to the manufacturer’s instructions. The
uorescence of the samples was always adjusted for the fluo-
escence of the diluent before evaluation. The measurement
ange of the assay was  1 to 200 g/L and the upper normal
imit was considered equal to the highest value recorded in over
00 healthy subjects in our laboratory: 2.4 g/L. Coefficients of
variation, based on 3 control samples, analyzed in duplicate, on
18 occasions, were between 1.8% and 3.6% within assays and
between 6.4% and 10% between assays.
Measurement of fecal ECP. The fecal levels of ECP
were measured using the Immulite 2000 (Siemens Medical So-
lutions Diagnostics, Tarrytown, New York), according to the
manufacturer’s instructions. The optimal sample dilution for
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with the measurements by immunoassay. Samples diluted at
1:40 or more with PBS showed good linearity of the assay system,
whereas samples diluted at 1:20 with PBS showed a higher level
than theoretically expected. This was considered to be due to
possible interference present in the stool. Therefore, the samples
were diluted at 1:40 or more with PBS. The measurement range of
the assay was 0.4 to 70 g/g and the upper normal limit was
onsidered equal to the highest value recorded in over 100 healthy
ubjects in our laboratory: 1 g/g. Intra-assay coefficient of varia-
ion (CV) was 9.1%, interassay CV was 12.5%.
Measurement of calprotectin. Fecal calprotectin
as measured by a commercially available quantitative enzyme-
inked immunoassay (Calprest, Eurospital, Trieste, Italy). The
upernatants were diluted 1:50 and 100 mL of each sample were Cdded to the wells of a microtiter plate and incubated at room
emperature for 45 minutes. After the plate was washed 4 times
ith diluted washing solution, 100 mL of purified rabbit anti-
alprotectin antibodies conjugated with alkaline phosphatase
ere added and incubated for 45 minutes at room temperature.
second washing procedure was performed and 100 mL of
nzyme substrate solution were added to each well and the
ptical density was read at 405 nm by a single biologist unaware
f the clinical diagnosis. Calprotectin concentration was calcu-
ated from the standard curve obtained with the kit standards
nd expressed as mg/g of stool.
According to manufacturer’s instructions the cutoff point
as 50 g/kg.
Intra-assay CV calculated on 20 samples was 5.2%, interassayV was 7.1%.
, and alternating bowel movements IBS.
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d-IBS
ECP values (g/g) 1.0  1.1
Tryptase values (g/L) 1.3  0.9
Calprotectin values (g/kg) 33  29
NOTE. The whole study group consisted of patients with IBS not relate
movements: diarrhea-predominant IBS, constipation predominant IBS SD) in the Whole Study Group
c-IBS a-IBS
1.2  1.3 1.2  1.6 Not significant
1.4  0.8 1.2  0.9 Not significant
43  39 32  32 Not significant
d to FH plus FH patients, subdivided according the frequency of the bowel
